For research use only. Not for therapeutic Use.
SB 204990 is a potent and specific inhibitor of ATP citrate lyase (ACLY) enzyme.
SB204990 (SB) is a specific inhibitor of ACLY enzyme. SB204990 treatment leads to a decrease in cytosolic Ac-CoA level and is thus expected to decrease acetylated and active β-catenin levels[1].
SB 204990, when administered orally to rats, is absorbed into the systemic circulation. When administered in the diet (0.05-0.25%, w/w) for 1 week, SB 204990 causes a dose-related decrease in plasma cholesterol (by up to 46%) and triglyceride levels (by up to 80%) in rats. SB 204990 (25 mg/kg per day) also decreases plasma cholesterol levels (by up to 23%) and triglyceride levels (by up to 38%) in the dog, preferentially decreasing low-density lipoprotein compared with high-density lipoprotein cholesterol levels[2].
| Catalog Number | I011062 |
| CAS Number | 154566-12-8 |
| Synonyms | 2-[(3S,5R)-5-[6-(2,4-dichlorophenyl)hexyl]-3-hydroxy-2-oxooxolan-3-yl]acetic acid |
| Molecular Formula | C18H22Cl2O5 |
| Purity | ≥95% |
| InChI | InChI=1S/C18H22Cl2O5/c19-13-8-7-12(15(20)9-13)5-3-1-2-4-6-14-10-18(24,11-16(21)22)17(23)25-14/h7-9,14,24H,1-6,10-11H2,(H,21,22)/t14-,18+/m1/s1 |
| InChIKey | YTRNLFYTHYWDAU-KDOFPFPSSA-N |
| SMILES | C1C(OC(=O)C1(CC(=O)O)O)CCCCCCC2=C(C=C(C=C2)Cl)Cl |
| Reference | [1]. Shares BH, et al. Active mitochondria support osteogenic differentiation by stimulating β-catenin acetylation. J Biol Chem. 2018 Oct 12;293(41):16019-16027. [2]. Pearce NJ, et al. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem J. 1998 Aug 15;334 ( Pt 1):113-9. |
